Home > Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
Dr Michele Tameris [Senior Research Officer: SATVI]
Dr Angelique Luabeya [Senior Research Officer - SATVI]
Host: Prof Mark Hatherill [Director: SATVI]
Dr Tameris and Dr Luabeya are both senior research officers at South African Tuberculosis Vaccine Initiative (SATVI), based at the Worcester research site. Dr Tamerisis is current PI of the Novavax trial and Dr Luabeya was PI during conceptualisation and planning phase.